Casdatifan Shows Activity Across Kidney Cancer Cohorts

Company Arcus Biosciences Event Type Clinical Data Update (ARC-20 cohorts) Modality Small molecule; oral HIF-2α inhibitor Asset Casdatifan (AB521) Target HIF-2α Disease Area Clear-cell renal cell carcinoma Summary Arcus disclosed new ARC-20 cohort results for the HIF-2α inhibitor casdatifan in clear-cell renal carcinoma. The breadth…